Top R&D budgets of 2022

Today's Big News

Mar 27, 2023

Musk's Neuralink seeks a clinical trial partner as it awaits FDA go-ahead: Reuters


From cell therapies to US-made ingredients, White House outlines new drug manufacturing goals


Top 10 pharma R&D budgets in 2022


#FierceMadness 2023: Dupixent shines again but Caplyta steals the show, as your Elite 8 bracket awaits


Vertex doubles down on CRISPR Tx and diabetes in new $100M deal

 

Featured

Musk's Neuralink seeks a clinical trial partner as it awaits FDA go-ahead: Reuters

Seemingly undeterred by reports earlier this month that the FDA had rejected an early 2022 request from Neuralink to begin a clinical trial of its brain implant, Elon Musk's brain-computer interface company is reportedly plowing ahead with plans for human testing.
 

Top Stories

From cell therapies to US-made ingredients, White House outlines new drug manufacturing goals

Looking to tackle issues ranging from climate change to cell therapy production, the Biden Administration has issued a panoply of biomanufacturing targets.

Top 10 pharma R&D budgets in 2022

The latest R&D budget rankings looks a lot like the 2021 list, but Sanofi cracked the list this year and shifts in positions occurred, like Merck reaching the podium after jumping Pfizer for third place.

#FierceMadness 2023: Dupixent shines again but Caplyta steals the show, as your Elite 8 bracket awaits

If it’s March, it must be #FierceMadness, Fierce Pharma Marketing’s annual take on the March Madness NCAA basketball tournament and bracket mania—with a pharma twist.

Vertex doubles down on CRISPR Therapeutics and diabetes in new $100M deal

Historically known for developing a handful of cystic fibrosis treatments, Vertex is now going deeper into diabetes and its work with CRISPR Therapeutics in a new $330 million deal.

Look out, Lilly. Novartis touts 'consistent benefit' for Kisqali in broad early-stage breast cancer

Novartis' highly anticipated NATALEE trial reported a positive readout, showing Kisqali could pare back disease recurrence in an early breast cancer population that's broader than Eli Lilly's Verzenio.

AbbVie, lifting the lid on life at the company, puts staff at heart of campaign to mark 10-year anniversary

AbbVie is 10 years old. To get the message out, the Big Pharma has turned to its critical resource: its employees. Across a blog post and social media updates, AbbVie has made employees the primary voice of the campaign to enable them to “express their pride” and show what it’s like to work at the company.

Jounce jilts Redx for Concentra's surprise merger offer, plans to lay off 84% of workforce

Only two weeks after crashing Redx Pharma’s planned reverse merger into Jounce Therapeutics, Concentra Biosciences’ unsubtle tactics appear to have paid off as it walks home with Jounce.

FDA outlines regulatory transition plan for COVID tests, devices as public health emergency wraps up

The FDA has laid down a path for the developers of COVID-19 tests and other pandemic-focused medical devices to finally make the transition to the foreseeable regulatory future, where the coronavirus will be treated as more endemic than emergency—and the agency is urging companies to get their paperwork in ASAP.

Novo's high-dose Rybelsus win tees up regulatory filings—and new rivalries

Even as Novo Nordisk rides the momentum of Rybelsus' hot launch, the company is testing higher-dose versions of the diabetes drug that could broaden its reach in a competitive market. Now, as part of the effort, the company is declaring a late-stage win.

Mammography AI maker iCad lays off another 28% of workers as losses grow, revenues shrink

Only a few months after it quietly conducted a reduction in force, iCad is once again laying off another chunk of its workers.

Gamida lays off 17%, ditches NK cell therapy work to keep blood cancer drug on track

More than a year after Gamida Cell slimmed down its workforce, the biotech has again resorted to laying off staff to keep the long-delayed plans for its blood cancer treatment omidubicel on the road.

DeepGlioma AI classifies brain tumors within 90 seconds—and with 93% accuracy, study finds

An artificial-intelligence-powered screening tool could make it easier for doctors to decide on the best treatment route for patients with certain types of brain tumors, according to a newly published study.
 
Fierce podcasts

Don't miss an episode

'The Top Line': Fierce Medtech's annual Fierce 15 honorees

This week on "The Top Line," we discuss Fierce Medtech’s annual Fierce 15 report and startups that made the cut. We also cover Illumina and Carl Icahn's proxy battle and more of this week's top headlines.

 

Resources

Whitepaper

Plan for scalable process liquid and buffer preparation

Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation.
Whitepaper

US/EU Governance: The Importance of Company Culture and Proven, Real-World Solutions

This paper describes the key elements of good US/EU corporate governance for US-based biopharma companies in operating Europe.
Executive Summary

Optimizing drug discovery in a fast-moving market

Read about the latest survey results from over 200 biopharma executives and the changing approaches to building biologic drug development pipelines.
Whitepaper

Answering your specific questions about mRNA/saRNA manufacturing

Have you had your questions about mRNA/saRNA manufacturing unanswered during a webinar; have no fear, we have you covered here.
Whitepaper

Proven Pharmaceutical Go-To-Market Model

Download Herspiegel Consulting’s Go-To-Market Model, based on 100+ launches, to learn the critical components, and timelines for commercial success.

Whitepaper

Intranasal Drug Product Development: Formulation to Manufacturing

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?
Whitepaper

Running Decentralized Trials at Scale

Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment.
Research

Step-wise strategy to address process characterization and late phase development

Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development.

Case Study

A Strategy to Standardize Process Characterization & Late Phase Development

Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments.

Whitepaper

Designing an Optimal APAC Clinical Supply Chain

Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific.
Whitepaper

Key Clinical Supply Issues Sponsors Should Consider with their CRO

As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs.

Research

A Strategy to Standardize Process Characterization & Late Phase Development

Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments.

Whitepaper

Specialized Expertise for Management of Clinical Supply Budgets

For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management.
Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.
Whitepaper

Roles and Responsibilities of Specialized Clinical Supply Experts

How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis.
Whitepaper

Questions You Need to Ask Your CRO About Clinical Supply

Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial.
Whitepaper

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
 

Industry Events

 

Upcoming Fierce Events

3-4
Apr
San Diego, CA
1-3
May
May 1-3, 2023 | Jersey City, NJ
23
May
Free Virtual Event
12-14
Jun
San Diego, CA
13-14
Jun
Free Virtual Event

View all events